Council of State and Territorial Epidemiologists/CDC Surveillance Case Definition for Multisystem Inflammatory Syndrome in Children Associated with SARS-CoV-2 Infection - United States.

Abstract

Since may 14, 2020, cdc has conducted national surveillance for multisystem inflammatory syndrome in children (mis-c) associated with infection with sars-cov-2, the virus that causes covid-19, among persons aged <21>adddd

This report summarizes the evidence and rationale supporting the components of the cste/cdc mis-c surveillance case definition and describes the methods used to develop the definition. these methods included convening mis-c clinical experts (i.e., consultants): regarding identification of MIS-C and its distinction from other pediatric conditions, a review of available literature comparing MIS-C phenotype with that of pediatric COVID-19 and other hyperinflammatory syndromes, and retrospective application of different criteria to data from MIS-C cases previously reported to CDC.

The cste/cdc surveillance case definition for mis-c includes four important changes, in comparison with the 2020 cdc mis-c case definition. these changes are 1) no required duration of subjective or measured fever; 2) requirement of c-reactive protein ≥3.0 mg/dl to indicate systemic inflammation; 3) adjustments to criteria of organ system involvement to include addition of shock as a separate category and elimination of respiratory, neurologic, and renal criteria; and 4) new requirements on timing of positive sars-cov-2 laboratory testing relative to the mis-c illness. although mis-c is not a nationally notifiable condition and reporting is voluntary, cste and cdc recommend that all states and territories report all cases meeting confirmed, probable, or suspect criteria of the cste/cdc mis-c surveillance case definition beginning january 1, 2023, for cases with mis-c illness onset on or after that date: